BERKELEY, Calif. and MAINZ, Germany, May 17, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participating in two notable investor conferences in May, 2022, the H.C. Wainwright Global Investment Conference and the Equity Forum German Spring Conference.

H.C. Wainwright Global Investment Conference

Date: May 23-26, 2022
Location: Miami, Florida
Presentation: 7am ET, May 24, 2022

The H.C. Wainwright Global Investment Conference combines leading industry keynote speakers and presenting companies with investor one-on-one meetings and networking events.

To register for the event, please visit https://hcwevents.com/globalconference/.

Equity Forum German Spring Conference

Date: May 23-25, 2022
Location: Frankfurt, Germany
Presentation: 8:30am CET, Tuesday, May 24, 2022 – Conference Room II

The spring conference is a MiFiD II compliant event with over 100 listed companies taking part in corporate presentations, one-on-one meetings and networking events with investors, analysts, financial journalists, intermediaries and financial industry experts.

To register for the event, please visit https://equityforum.de/en/german-spring-conference

About ColoAlert
ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product…